Bellerophon Therapeutics (BLPH) Competitors $0.01 0.00 (-25.47%) (As of 12/18/2024 02:18 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendFinancialsInsider TradesSEC FilingsSustainabilityTrends BLPH vs. HSTO, PTEIQ, SRNE, NEXI, PKBO, BDRX, PRFX, TFFP, TCBP, and SEELShould you be buying Bellerophon Therapeutics stock or one of its competitors? The main competitors of Bellerophon Therapeutics include Histogen (HSTO), PolarityTE (PTEIQ), Sorrento Therapeutics (SRNE), NexImmune (NEXI), Peak Bio (PKBO), Biodexa Pharmaceuticals (BDRX), PainReform (PRFX), TFF Pharmaceuticals (TFFP), TC Biopharm (TCBP), and Seelos Therapeutics (SEEL). These companies are all part of the "pharmaceutical products" industry. Bellerophon Therapeutics vs. Histogen PolarityTE Sorrento Therapeutics NexImmune Peak Bio Biodexa Pharmaceuticals PainReform TFF Pharmaceuticals TC Biopharm Seelos Therapeutics Bellerophon Therapeutics (NASDAQ:BLPH) and Histogen (NASDAQ:HSTO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Do institutionals and insiders have more ownership in BLPH or HSTO? 10.6% of Bellerophon Therapeutics shares are held by institutional investors. 5.2% of Bellerophon Therapeutics shares are held by insiders. Comparatively, 3.3% of Histogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better earnings & valuation, BLPH or HSTO? Histogen has lower revenue, but higher earnings than Bellerophon Therapeutics. Bellerophon Therapeutics is trading at a lower price-to-earnings ratio than Histogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBellerophon Therapeutics$5.64M0.03-$19.83M-$0.84-0.01Histogen$19K6.21-$10.62M-$2.81-0.01 Is BLPH or HSTO more profitable? Company Net Margins Return on Equity Return on Assets Bellerophon TherapeuticsN/A N/A N/A Histogen N/A N/A N/A Which has more risk and volatility, BLPH or HSTO? Bellerophon Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Histogen has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Does the MarketBeat Community prefer BLPH or HSTO? Bellerophon Therapeutics received 312 more outperform votes than Histogen when rated by MarketBeat users. However, 58.33% of users gave Histogen an outperform vote while only 57.37% of users gave Bellerophon Therapeutics an outperform vote. CompanyUnderperformOutperformBellerophon TherapeuticsOutperform Votes31957.37% Underperform Votes23742.63% HistogenOutperform Votes758.33% Underperform Votes541.67% Does the media refer more to BLPH or HSTO? In the previous week, Bellerophon Therapeutics had 2 more articles in the media than Histogen. MarketBeat recorded 2 mentions for Bellerophon Therapeutics and 0 mentions for Histogen. Bellerophon Therapeutics' average media sentiment score of 0.50 beat Histogen's score of 0.00 indicating that Bellerophon Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Bellerophon Therapeutics Positive Histogen Neutral SummaryBellerophon Therapeutics beats Histogen on 7 of the 12 factors compared between the two stocks. Ad Porter & CompanyVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get Bellerophon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLPH vs. The Competition Export to ExcelMetricBellerophon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$122,000.00$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.0110.5990.0517.20Price / Sales0.03196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.045.094.784.78Net Income-$19.83M$151.83M$120.31M$225.60M7 Day PerformanceN/A-2.14%-1.92%-1.23%1 Month PerformanceN/A-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Bellerophon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLPHBellerophon Therapeutics0.8474 of 5 stars$0.01-25.5%N/A-62.5%$122,000.00$5.64M-0.0120Dividend AnnouncementAnalyst ForecastNews CoverageGap DownHSTOHistogenN/A$0.22+975.0%N/A-91.3%$918,000.00$19,000.00-0.017Gap UpPTEIQPolarityTEN/A$0.08flatN/A+18.1%$615,000.00$810,000.00-0.0460High Trading VolumeSRNESorrento TherapeuticsN/A$0.00-26.7%N/A-96.5%$606,000.00$62.84M0.00800Analyst ForecastGap DownNEXINexImmuneN/A$0.38+64.1%N/A-89.7%$526,000.00N/A-0.016PKBOPeak BioN/A$0.02-67.9%N/A-81.3%$520,000.00$370,000.00-0.143Gap DownHigh Trading VolumeBDRXBiodexa Pharmaceuticals1.5902 of 5 stars$4.27+1.7%$200.00+4,583.8%N/A$508,000.00$83,000.000.0021PRFXPainReform1.7798 of 5 stars$2.93-5.8%$8.00+173.0%-47.6%$410,000.00N/A-0.024News CoverageGap UpTFFPTFF Pharmaceuticals2.1554 of 5 stars$0.07flat$44.00+67,592.3%N/A$289,000.00$730,000.00-0.0119Positive NewsTCBPTC Biopharm2.9794 of 5 stars$0.54+2.1%$3.00+455.6%-97.4%$286,000.00$4.76M0.0041News CoverageGap DownSEELSeelos TherapeuticsN/A$0.30-14.5%N/A-99.8%$110,000.00$2.20M0.0020 Related Companies and Tools Related Companies Histogen Alternatives PolarityTE Alternatives Sorrento Therapeutics Alternatives NexImmune Alternatives Peak Bio Alternatives Biodexa Pharmaceuticals Alternatives PainReform Alternatives TFF Pharmaceuticals Alternatives TC Biopharm Alternatives Seelos Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLPH) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellerophon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
